Unilever, the consumer goods giant behind brands like Dove and Hellmann's, is reportedly considering a bid for US supplements brand Thorne. According to the Financial Times, a deal could value Thorne at up to $4 billion, signaling a major bet on the booming wellness market.
The potential acquisition is part of CEO Fernando Fernandez's broader strategy to steer Unilever away from slower-growing pantry staples and detergents toward higher-margin categories like beauty and wellbeing. Thorne, which sells vitamins, minerals, and other dietary supplements, would join a portfolio that already includes Olly Nutrition, SmartyPants Vitamins, and Nutrafol.
What's Driving the Deal?
Unilever has been reshaping its product lineup for years, but the Thorne bid would be its biggest supplement play yet. The company has already made several smaller acquisitions in the space, including Olly Nutrition in 2019 and SmartyPants Vitamins in 2020. Thorne, however, represents a step up in both size and ambition.
The supplements market has been growing steadily as consumers increasingly focus on health and wellness. According to industry data, the global dietary supplements market was valued at over $150 billion in 2023 and is expected to continue expanding. That growth has attracted interest from multiple bidders, including Haleon, the consumer healthcare company that spun off from GSK in 2022. Reuters has reported that Haleon is also circling Thorne, underscoring the competitive landscape.
Thorne's price tag tells a striking story. The brand was acquired by L Catterton, a private equity firm backed by luxury goods giant LVMH, for $680 million in 2023. A potential $4 billion valuation would represent a nearly sixfold increase in just two years, implying that buyers expect strong growth and pricing power in the US market.
What It Means for Investors
For Unilever shareholders, a $4 billion Thorne deal would raise the stakes on the company's wellness pivot. Paying a premium price typically means booking more goodwill—the amount paid above the target's tangible assets—which can pressure return on invested capital if profits don't ramp up quickly.
In the supplements industry, cost-cutting opportunities are often more limited than in other consumer goods deals. Unlike a detergent or food acquisition, where manufacturing and supply chain efficiencies can be relatively easy to achieve, supplements rely heavily on brand trust, quality control, and consumer loyalty. That means the math on a Thorne deal would depend more on keeping sales growing and maintaining pricing power than on near-term cost savings.
If Unilever wins the bidding, investors are likely to judge the deal less on immediate synergies and more on whether Thorne can continue to scale without losing brand momentum. The company's ability to integrate Thorne into its existing wellness portfolio—and to cross-sell products through its global distribution network—will be key.
The broader context also matters. Unilever's shift toward beauty and wellbeing comes as traditional consumer goods face headwinds from rising input costs and changing consumer habits. The company has been selling off slower-growing brands, such as its tea business, to focus on higher-margin categories. A Thorne acquisition would be a clear signal that Fernandez is doubling down on that strategy.
However, the deal is not without risks. The supplements industry is highly regulated, and any quality or safety issues could damage brand reputation. Additionally, the US market is crowded with competitors, from established players like Nestlé's Garden of Life to newer direct-to-consumer brands. Unilever will need to differentiate Thorne in a space where consumers have many choices.
For everyday investors, the key takeaway is that Unilever's wellness pivot is accelerating, but the success of that strategy will hinge on execution. A $4 billion bet on Thorne would test whether the company can generate strong returns from its beauty-and-wellbeing shift, not just change what it sells. Investors should watch for updates on the bidding process and any details on how Unilever plans to integrate Thorne if it wins.
For more on the broader dealmaking landscape, see our coverage of Dealmakers Busy: Safran Eyes Exail, ON Semi Buys Synaptics, Unilever Shops Thorne.
